Výsledky vyhledávání - "Ying-qing Wang"

Akademický článek

Generation of an induced pluripotent stem cell line, FJMUUHi001-A, from a hereditary Parkinson's disease patient with homozygous mutation of c.189dupA in PARK7

Autor: Zhi-ting Chen, Zhen-hua Zhao, Li-na Chen, Fei Fan, Guo-en Cai, Hui-dan Weng, Ying-qing Wang, Lian-ming Liao, Xiao-chun Chen, En Huang, Qin-yong Ye

Publikováno v: Stem Cell Research, Vol 51, Iss , Pp 102175- (2021)

PARK7 mutations are accountable for the inherited Parkinson's disease. An induced pluripotent stem cell (iPSC) line FJMUUHi001-A was generated by expressing five reprogramming factors, OCT3/4, SOX2, c-MYC, KLF4 and BCL-XL, in peripheral blood mononuc

Externí odkaz: https://doaj.org/article/0605d8f7faa94284b3ec706c7cfc656b

Zobrazit plný text záznamu

Akademický článek

Marine-Derived Angiogenesis Inhibitors for Cancer Therapy

Autor: Ying-Qing Wang, Ze-Hong Miao

Publikováno v: Marine Drugs, Vol 11, Iss 3, Pp 903-933 (2013)

Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities. Compared with the drugs in the clinic, these agents d

Externí odkaz: https://doaj.org/article/32c046ccea194c2a8bddf5cf5fb6439b

Zobrazit plný text záznamu

Data from Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non–Small Cell Lung Cancer Cells

Autor: Ze-Hong Miao, Ying-Qing Wang, Chang-Qing Tian, Xia-Juan Huan, Qian Wu, Lin Sun

Inhibitors targeting bromodomain and extraterminal (BET) proteins are promising anticancer drugs. The emergence of drug resistance during treatments will impair their therapeutic effectiveness. To investigate the mechanisms of acquired resistance to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312548b0fccedc6ed6c17aca2befd815
https://doi.org/10.1158/1541-7786.c.6545633.v1

Zobrazit plný text záznamu

Data from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189

Autor: Ze-Hong Miao, Jing-Kang Shen, Jian Ding, Yi Chen, Lin-Jiang Tong, Lan-Ping Ma, Xia-Juan Huan, Jun-Mei Yi, Tao Meng, Ying-Qing Wang, Wei Wang

Colchicine site–targeted tubulin inhibitors are a promising type of anticancer drugs. MT189 is a new derivative of MT119, a previously reported colchicine site–binding antitubulin agent. In this study, MT189 was demonstrated to retain the propert

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46801cd2710063bef7c66d16d65c4bec
https://doi.org/10.1158/1535-7163.c.6536575.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání